Pharmafile Logo

News and Press Releases

Concr launches trial using digital twins for outcome prediction in breast cancer

10 July 2024, London United Kingdom – Concr announces that first patients have been recruited to the VISION trial, an observational clinical study evaluating Concr’s therapeutic response predictive algorithm defining...

Category: Biotechnology
Posted: July 10, 2024

Concr
info@concr.co
11 Milbrook, Esher, KT10 9EJ, UK

Nxera Pharma Receives US$10m from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone

27 June 2024, Tokyo, Japan and Cambridge, UK - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration...

Category: BioManufacturing, Other, Pharmaceutical
Posted: June 28, 2024

Nxera Pharma
Midtown East 9-7-2 Akasaka Minato-ku Tokyo 107-0052

Life Sciences organizations expect more than one-fifth of revenue to come from connected health in the next five years

Sixfold increase in biopharma organizations with market-ready connected health products since 2021; three in four medtech organizations already have connected health products on the market June 18 2024 - Paris,...

Category: Biotechnology, Other
Posted: June 18, 2024

Capgemini
UK Head Office, Capgemini Services, 40 Holborn Viaduct, London, EC1N 2PB

Oxford Drug Design and CRUK Scotland Institute awarded MRC grant funding to advance novel cancer therapeutics discovery

Collaboration to use genetically engineered mouse models to validate a new approach to cancer therapy 4 June 2024 - United Kingdom - The CRUK (Cancer Research UK) Scotland Institute and Oxford...

Category: Drug Discovery
Posted: June 10, 2024

Oxford Drug Design
contactus@oxforddrugdesign.com
Oxford Drug Design Lt,d Oxford Centre for Innovation, New Road, Oxford, OX1 1BY, UK

Owlstone Medical Secures $6.5m to Support Development of Breath-based Diagnostics for Infectious Disease

$5m equity investment and initial $1.5m grant funding committed by the Bill & Melinda Gates Foundation for development of breath-based diagnostic solutions to improve outcomes in the developing world Funding...

Category: Biotechnology, Other
Posted: April 25, 2024

Owlstone Medical
breathbiopsy@owlstone.co.uk
Owlstone Ltd, 127 Cambridge Science Park, Milton Road, Cambridge, CB4 0GD, UK

Eisbach and Cancer Focus Fund Announce $4.5m Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumours

Eisbach is enabling the potential of synthetic lethality by developing novel compounds to exploit molecular vulnerabilities uniquely present in many hard-to-treat cancers 21 March 2024 -- Martinsried, Germany and Texas, US...

Category: Biotechnology, Pharmaceutical
Posted: March 21, 2024

Eisbach Bio
info@eisbach.bio
Am Klopferspitz 19, 82152 Planegg, Germany

Calluna Pharma launches and announces €75m Series A financing to develop novel therapies for inflammatory and fibrotic diseases

Clinical stage company formed from the merger of Oxitope Pharma and Arxx Therapeutics Calluna Pharma has a pipeline of selective antibodies targeting immunological diseases New company to complete multiple clinical...

Category: Drug Discovery, Pharmaceutical
Posted: January 23, 2024

Calluna Pharma
Nytt Foretak AS, Grundingen 6, 0250 Oslo, Norway.

CellVoyant secures £7.6m seed funding to accelerate the development of stem cell therapies with AI

Investment will make stem cell-based therapies more efficient, scalable and cost-effective 16 January 2024 -- Bristol, UK -- CellVoyant, an AI-first biotechnology spin-out from the University of Bristol, UK, accelerating...

Category: Biotechnology
Posted: January 16, 2024

CellVoyant
info@cellvoyant.com
Origin Workspace 40 Berkeley Square, Bristol BS8 1HP

Antiverse and GlobalBio, Inc extend collaboration to advance antibody cancer therapeutics

Collaboration successfully identified antibodies with therapeutic potential as checkpoint inhibitors in oncology Two antibodies showing high specificity for PD-1 are now being progressed to preclinical development Project leveraged Antiverse’s AI-driven...

Category: Biotechnology
Posted: October 16, 2023

Antiverse
info@antiverse.io
MediCentre, Heath Park, Cardiff CF14 4UJ

Orakl Oncology raises €3 million to develop its techbio platform forprecision oncology

4 October 2023 -- Paris, France -- Orakl Oncology, a precision oncologystart-up, today announces that it has raised €3m to develop its techbio platform thatintegrates best-in-class biology with real-world patient...

Category: Biotechnology
Posted: October 9, 2023

Orakl Oncology
contact@orakl-oncology.com
39 rue Camille Desmoulins 94800 Villejuif, France

Additional Analytical Laboratory and Spray Drying Investments

5 October 2023 -- New Jersey, US -- Experic, a contract development and manufacturing organisation (CDMO) and clinical supply services company serving the biopharmaceutical industry, announced today the successful completion of...

Category: Manufacturing and Packing
Posted: October 5, 2023

Experic
info@expericservices.com
2 Clarke Drive, Cranbury, NJ 08512

Start Codon Invites Life Sciences Leaders, Founders, and Investors to Innovation Showcase 2023

Hybrid event is taking place 10 October 2023, in Cambridge, UK Programme features presentations from five disruptive portfolio companies and networking opportunities with Start Codon’s extended portfolio Registration for Innovation...

Category: Other
Posted: September 26, 2023

Start Codon
jennie@startcodon.co
c/o Milner Therapeutics Institute, Jeffrey Cheah Biomedical Centre, Puddicombe Way, Cambridge Biomedical Campus, Cambridge CB2 0AW